COMPANIES COVERED
Bluebird BioDownload FREE Report Sample
Download Free sampleThalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in U.S.
Alpha Thalassemia Market contains market size and forecasts of Alpha Thalassemia in Global, including the following market information:
Global Alpha Thalassemia Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Alpha Thalassemia market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Iron Chelating Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Alpha Thalassemia include Bluebird Bio, Novartis, Kiadis Pharma and Acceleron Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Alpha Thalassemia companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Alpha Thalassemia Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Alpha Thalassemia Market Segment Percentages, by Type, 2021 (%)
Iron Chelating Drugs
Gene Therapy
Global Alpha Thalassemia Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Alpha Thalassemia Market Segment Percentages, by Application, 2021 (%)
Hospitals
Private Clinics
Other
Global Alpha Thalassemia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Alpha Thalassemia Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Alpha Thalassemia revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Alpha Thalassemia revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bluebird Bio
Novartis
Kiadis Pharma
Acceleron Pharma
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
